Medicaid, CHIP cut funds for youth gender-affirming care

Clinical takeaway: Federal payment for minors already on hormone therapy will taper off for up to six months past the effective date, so patients on therapy now may hit the end of federal payment by next spring. 

Federal Medicaid and Children's Health Insurance Program (CHIP) funds will no longer pay for puberty blockers, cross-sex hormone therapy, or gender-related surgery in patients under 18. CMS issued an announcement of the final rule on August 11, with an effective date of Oct 13, 2026. 

The rule applies only to federal matching dollars. States may choose to continue covering the same services with state funds, and commercial plans are unaffected. Whether a given patient loses access will likely depend on where they live and how they are insured. Patients already on hormone therapy get a tapering-off period of up to six months from the effective date. 

Mental health coverage is carved out as an exception. CMS says Medicaid's Early and Periodic Screening, Diagnostic, and Treatment provisions continue to require comprehensive mental health services for eligible children, and CHIP continues to require medically necessary mental health coverage. Counseling, psychiatric care, and evaluation remain payable. 

CMS ties the decision to a Department of Health and Human Services (HHS) review of national and international research that the agency says documented evidence gaps and safety concerns, and cites the United Kingdom's Cass Report along with restrictions adopted by other countries and some US states. The agency attributes risks including infertility, impaired sexual function, reduced bone density, and altered brain development, and describes the interventions as "sex-rejecting procedures." Both the risk characterization and the terminology are the agency's, not clinical consensus. 

CMS also points to specialty societies clarifying their positions, including the American Society of Plastic Surgeons (ASPS). The society's February 2026 position statement recommends surgeons delay gender-related breast, chest, genital, and facial surgery until at least age 19. But its scope is surgical: the statement makes no recommendation on puberty blockers or hormone therapy, though it concludes the evidence does not show a favorable risk-benefit ratio for the combined endocrine and surgical pathway in minors. ASPS notes it is a position statement, not a clinical practice guideline.

"Today, we are ending federal taxpayer funding for sex-rejecting procedures on children," said Robert Kennedy Jr., HHS secretary. "These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve." 

Source: CMS. (2026 Aug 11) CMS Ends Federal Medicaid and CHIP Funding for Sex-Rejecting Procedures for Children and Youth